Translational and Clinical Pharmacology

Korean Society for Clinical Pharmacology and Therapeutics (대한임상약리학회)
권호 표지
DOI QR코드

DOI QR Code

Five years of the CiPA project (2013-2018) - what did we learn?

  • Yim, Dong-Seok (Department of Clinical Pharmacology and Therapeutics, Seoul St. Mary's Hospital)
  • Published : 2018.12.15
⟨ Previous Next ⟩

Abstract

Cases of drug-induced QT prolongation and sudden cardiac deaths resulted in market withdrawal of many drugs and world-wide regulatory changes through accepting the ICH guidelines E14 and S7B. However, because the guidelines were not comprehensive enough to cover the electrophysiological changes by drug-induced cardiac ion channel blocking, CiPA was initiated by experts in governments and academia in the USA, Europe, and Japan in 2013. Five years have passed since the launch of the CiPA initiative that aimed to improve the current ICH guidelines. This report reviews the current achievements of the CiPA initiative and explores unresolved issues.

Keywords

References

  1. Brown A. Drugs, hERG and sudden death. Cell Calcium 2004;35:543-547. doi: 10.1016/j.ceca.2004.01.008.
  2. Delpon E, Valenzuela C, Tamargo J. Blockade of cardiac potassium and other channels by antihistamines. Drug Saf 1999;21 Suppl 1:11-18; discussion 81-17. doi: 10.2165/00002018-199921001-00003.
  3. Shah RR. Drugs, QTc Interval prolongation and final ICH E14 guideline. Drug Saf 2005;28:1009-1028. doi: 10.2165/00002018-200528110-00003.
  4. Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 2010;159:49-57. doi: 10.1111/j.1476-5381.2009.00487.x.
  5. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45. https://doi.org/10.1016/S0008-6363(02)00846-5
  6. Li Z, Ridder BJ, Han X, Wu WW, Sheng J, Tran PN, et al. Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the Ci PA Initiative. Clin Pharmacol Ther 2018. doi: 10.1002/cpt.1184.
  7. O'Hara T, Virag L, Varro A, Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 2011;7:e1002061. doi: 10.1371/journal.pcbi.1002061.
  8. Li Z, Dutta S, Sheng J, Tran PN, Wu W, Chang K, et al. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-a-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology. Circ Arrhythm Electrophysiol 2017;10:e004628. doi: 10.1161/CIRCEP.116.004628.
  9. Crumb WJ, Jr., Vicente J, Johannesen L, Strauss DG. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J Pharmacol Toxicol Methods 2016;81:251-262. doi: 10.1016/j.vascn.2016.03.009.
  10. Dutta S, Chang KC, Beattie KA, Sheng J, Tran PN, Wu WW, et al. Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment. Front Physiol 2017;8:616. doi: 10.3389/fphys.2017.00616.
  11. Elkins RC, Davies MR, Brough SJ, Gavaghan DJ, Cui Y, Abi-Gerges N, et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment. J Pharmacol Toxicol Methods 2013;68:112-122. doi: 10.1016/j.vascn.2013.04.007.
  12. Mistry HB. Complexity vs. Simplicity: The Winner Is? Clin Pharmacol Ther 2017;101:326. doi: 10.1002/cpt.503.
  13. Mistry HB. Complex versus simple models: ion-channel cardiac toxicity prediction. PeerJ 2018;6:e4352. doi: 10.7717/peerj.4352.
  14. Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre MP, et al. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug- Induced Arrhythmias. Toxicol Sci 2017;155:234-247. doi: 10.1093/toxsci/kfw200.
  15. Johannesen L, Vicente J, Mason JW, Sanabria C, Waite-Labott K, Hong M, et al. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther 2014;96:549-558. doi: 10.1038/clpt.2014.155.
  16. Vicente J, Zusterzeel R, Johannesen L, Mason J, Sager P, Patel V, et al. Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study. Clin Pharmacol Ther 2018;103:54-66. doi: 10.1002/cpt.896.

Cited by

  1. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes vol.180, pp.2, 2018, https://doi.org/10.1093/toxsci/kfaa194